Alemtuzumab until minimal residual disease for chronic lymphocytic leukemia: Is it a new standard?
Goodman
Mark
M
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004334:Drug Administration Schedule; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D018365:Neoplasm, Residual; D016032:Randomized Controlled Trials as Topic; D016879:Salvage Therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab